Dalian Bio-Chem Co., Ltd. Class A

Dalian Bio-Chem Co., Ltd. Class A

SSSE:603360
9.42
CNY
+0.09
(+0.96%)
0.31EPS
60.19P/E
8.66BMarket Cap
Apr 23Next Earn

Total Valuation

CNY

As of September 30, 2026, Dalian Bio-Chem Co., Ltd. Class A carries a market capitalization of 8.66B, placing it among publicly traded companies globally. Its enterprise value stands at 9.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap8.66B
Enterprise Value9.73B

Important Dates

Dalian Bio-Chem Co., Ltd. Class A's next confirmed earnings release is scheduled for April 23, 2027.

Earnings Date4/23/2027

Share Statistics

As of September 30, 2026, Dalian Bio-Chem Co., Ltd. Class A has 706.22M shares outstanding.

Shares Outstanding706.22M

Valuation Ratios

As of September 30, 2026, Dalian Bio-Chem Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 60.19. The price-to-sales ratio is 5.82, and the price-to-book ratio stands at 6.20.

PE Ratio60.19
PS Ratio5.82
PB Ratio6.20
P/TBV Ratio8.23

Enterprise Valuation

As of September 30, 2026, Dalian Bio-Chem Co., Ltd. Class A trades at an EV/EBITDA multiple of 49.84 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.77 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 49.84 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 9.73B versus a market cap of 8.66B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales6.77
EV / EBITDA49.84
EV / EBIT49.84

Financial Position

As of September 30, 2026, Dalian Bio-Chem Co., Ltd. Class A maintains a current ratio of 2.70, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 65.24, indicating elevated leverage, while an interest coverage ratio of 5.38 demonstrates adequate ability to service its debt obligations.

Current Ratio2.70
Quick Ratio0.96
Debt / Equity65.24
Debt / EBITDA6.82
Interest Coverage5.38

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Dalian Bio-Chem Co., Ltd. Class A posted a return on equity (ROE) of 7.88, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 3.67, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.36M in revenue per employee across its workforce of 1,053.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)7.88
Return on Assets (ROA)3.67
Revenue Per Employee1.36M
Employee Count1,053.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Dalian Bio-Chem Co., Ltd. Class A recorded an income tax benefit of -13.80M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 199.64M, leaving 139.07M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax-13.80M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Dalian Bio-Chem Co., Ltd. Class A's stock has declined approximately 74.00% over the past 52 weeks. The 50-day moving average sits at 11.55, while the 200-day moving average is 19.15.

52-Week Price Change-74.00%
50-Day Moving Average11.55
200-Day Moving Average19.15

Income Statement

CNY

Over the twelve months ended September 30, 2026, Dalian Bio-Chem Co., Ltd. Class A generated 1.44B in revenue and converted that into 139.07M in net income, yielding earnings per share of 0.31. EBITDA reached 195.31M, while operating income came in at 237.25M.

Revenue1.44B
Gross Profit511.56M
Operating Income237.25M
Pretax Income199.64M
Net Income139.07M
EBITDA195.31M
EBIT195.31M
Earnings Per Share (EPS)0.31

Balance Sheet

CNY

As of September 30, 2026, Dalian Bio-Chem Co., Ltd. Class A holds 903.16M in cash and equivalents against 1.33B in total debt, resulting in a net debt position of 218.94M. Total book value stands at 1.40B, with working capital of 1.60B providing operational flexibility.

Cash & Cash Equivalents903.16M
Total Debt1.33B
Net Debt218.94M
Equity (Book Value)1.40B
Book Value Per Share1.98
Working Capital1.60B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-118.37M

Margins

Over the twelve months ended September 30, 2026, Dalian Bio-Chem Co., Ltd. Class A posted a gross margin of 35.59, reflecting its pricing power and cost economics. The operating margin of 16.51 and net profit margin of 9.68 provide insight into operational efficiency.

Gross Margin35.59
Operating Margin16.51
Pretax Margin13.89
Profit Margin9.68
EBITDA Margin13.59

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Dalian Bio-Chem Co., Ltd. Class A paid dividends of 0.05 per share. The dividend payout ratio of 11.81 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.75, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Dalian Bio-Chem Co., Ltd. Class A shareholders.

Dividend Per Share0.05
Payout Ratio11.81
Shareholder Yield2.75

Stock Splits

Dalian Bio-Chem Co., Ltd. Class A's most recent stock split took place on May 29, 2025 with a 5:7 split ratio.

Last Split Date5/29/2025
Split Ratio5:7

Scores

As of September 30, 2026, Dalian Bio-Chem Co., Ltd. Class A has an Altman Z-Score of 4.35, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.35